AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06713980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture:the choice of acupoints was based on the theory of traditional Chinese medicine (TCM). All needles were manually manipulated to achieve the deqi sensation
Study NCT06713044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Murottal Therapy Intervention Name: Murottal (Islamic verse recitation)
Description: To evaluate whether murottal recitations can reduce postoperative pain intensity and lower interleukin 6 levels, which are indicative of inflammation.
Study NCT06713044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classical Music Therapy Intervention Name: Classical Music Listening
Description: To evaluate the impact of classical music on reducing postoperative pain intensity and interleukin 6 levels in the body, thereby managing inflammation.
Study NCT05970718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Study NCT05526157 — intervention group
Intervention type: DRUG
Intervention: Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Description: Retrospective analysis using secondary data collection from various sources
Study NCT04965064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Neratinib.
Description: Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
Study NCT05970718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Solution for single ascending IV or SC administration per the protocol
Study NCT06713044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (in control arm)
Description: To serve as a control group no intervention
Study NCT06713512 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study NCT06714175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower Limb Strength Training Program with Visual Feedback
Description: This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
Study NCT06714331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplements
Description: Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
Study NCT06714331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Supplements
Description: Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
Study NCT06714383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.
Study NCT06714383 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pirarubicin
Description: Pirarubicin: 60 mg/m2，IV，d1-2
Study NCT06714383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: Pirarubicin: 60 mg/m2，IV，d1-2
Study NCT06714383 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lobaplatin
Description: LobaplLatin: 40 mg/m2,，IV，d1
Study NCT06714383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: LobaplLatin: 40 mg/m2,，IV，d1
Study NCT06710977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safety of intracameral levofloxacin in cataract surgery
Description: Intracameral levofloxacin (0.1ml/0.5mg)
Study NCT06710977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safety of intracameral levofloxacin in cataract surgery
Description: Intracameral levofloxacin (0.1ml/0.5mg)
Study NCT06710977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of intracameral cefazolin in cataract surgery
Description: Intracameral cefazolin (0.1ml/1mg)
Study NCT06710977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of intracameral cefazolin in cataract surgery
Description: Intracameral cefazolin (0.1ml/1mg)
Study NCT06711146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolically Armed CD19 CAR-T cells
Description: Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
Study NCT06712394 — intervention group
Intervention type: PROCEDURE
Intervention: IPACK
Description: The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.
Study NCT06711367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell show do behavior management technique
Description: tell show do behavior management technique about the the diagnosis and procedures of dental restoration
Study NCT06711367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a costume-designed storybook
Description: a costume-designed storybook explaining the diagnosis and procedures of dental restoration
Study NCT06711016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc
Description: ECMO flow, IABP , ventilator support parameters, temperature management level and time
Study NCT06711016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc
Description: ECMO flow, IABP , ventilator support parameters, temperature management level and time
Study NCT06712472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg BID)
Description: Olaparib 300mg Bid during one year.
Study NCT06714604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX or gemcitabine-nab-paclitaxel
Description: 4 months if treatment
Study NCT06714604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine-nab-paclitaxel
Description: 6 months of treatment
Study NCT06711770 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
Study NCT06711328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New oropharyngeal airway
Description: This product is produced and sold by Shanghai Elifu Medical Technology Co., LTD., and has been officially put into clinical use in March 2023.The product is named oropharyngeal airway for disposable endoscope, which is composed of nasal plug, bite, oropharyngeal channel, oxygen supply tube, lanyard and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.The model used in this study is JK (Oropharyngeal airway for endoscope with end-expiratory carbon dioxide Collection) with L/M/S three specifications, which is used to prevent airway obstruction caused by backward tongue fall during endoscopic surgery/examination, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time
Study NCT06712797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Description: Participants will receive a Fitbit (Inspire 3, Google LLC, Mountain View, CA, USA) to encourage and self-monitor Physical Activity (PA) using active minutes, which approximate moderate-to-vigorous PA.~Fitbits will be synced to a HIPAA-compliant platform created by Moffitt's Biostatistics and Bioinformatics Shared Resource (BBSR).~Study personnel will view active minutes to provide individualized feedback and encourage progression. Weekly feedback will encourage participants to increase active minutes by 10% until achieving ≥ 150 minutes to meet cancer prevention recommendations.~Participants who reach ≥ 150 active minutes will be encouraged to maintain or exceed recommendations.
Study NCT06712797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition (N)
Description: Participants will undergo counseling at baseline (T0) to address nutritional symptoms and provide targets for daily calories and protein following a Mediterranean diet. This diet includes a high intake of vegetables, legumes, fruits, and unsaturated fatty acids, low intake of saturated fatty acids, and a moderately high intake of fish.~Total caloric intake will be calculated. A standard breakdown of 40% carbohydrates, 30% fats and 30% protein will be used. Individuals will review this calculation during their office encounters and follow these values using the FitBit, application, which will adjust to their daily energy expenditure.~Additional counseling (in-person or via Zoom) will occur at baseline (T0) + 12 weeks to gauge progress toward calorie and protein targets, monitor weight change, and guide dietary changes.~Participants will log daily food intake and self-monitor progress toward calorie and protein goals.
Study NCT06711029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional needle irrigation
Description: Conventional needle irrigation method was applied. As a final irrigation, 6 ml NaOCl was applied with 60 seconds of needle irrigation followed by 60 seconds of rest.
Study NCT06711029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Ultrasonic Irrigation with 3*20 sn
Description: In the final irrigation, 6 ml (3×2 ml) NaOCl was activated by PUI for 20 seconds in 3 cycles (60 seconds total). Before each cycle, 2 ml of NaOCl solution was refreshment.
Study NCT06711029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Ultrasonic Irrigation with 6*10 sn
Description: For the final irrigation, 6 ml (6×1 ml) NaOCl was activated with PUI for 10 seconds in 6 cycles (60 seconds total). Before each cycle, 1 ml of NaOCl solution was refreshment.
Study NCT06393634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone injection
Description: A single injection of testosterone
Study NCT06393634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: A daily dose of testosterone gel
Study NCT06393634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Oral
Description: A twice-daily pill of testosterone pill to swallow
Study NCT06544642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5502
Description: Oral
Study NCT04966962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum and urine metabolomics
Description: serum and urine samples will be collected for metabolomics analysis
Study NCT05855824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applesauce Pouch
Description: One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
Study NCT05855824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Applesauce Pouch
Description: One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
Study NCT05855824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit-vegetable puree blend
Description: One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
Study NCT04841967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TELL Tool Intervention
Description: A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
Study NCT04841967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eBook Attention Control
Description: A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Neck Manual Therapy
Description: Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neck Stretches
Description: Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scar massage
Description: Digital manipulation of the scar itself in circles.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Scar massage
Description: Digital manipulation of the scar itself in circles.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Exercises
Description: Stemple Voice Exercises
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Voice Exercises
Description: Stemple Voice Exercises
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Anterior Neck Manual Therapy
Description: Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pain Neuroscience Education
Description: Will discuss how pain will as a result of the surgical intervention.
Study NCT06383091 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Neck Stretches
Description: Will ask patient to look down as a neck stretch held for 20 seconds x3.
Study NCT04776031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R:GEN Laser System
Description: Laser Treatment
Study NCT05712876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-0045
Description: Interleukin-22 agonist
Study NCT05712876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT06515977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXI (Group A)
Description: Patients in Group A will undergo colonoscopy with TXI.
Study NCT06515977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TXI followed by WLI (Group B)
Description: Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
Study NCT06515977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WLI (Group C)
Description: Patients in Group C will undergo colonoscopy with WLI.
Study NCT06515977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WLI followed by TXI (Group D)
Description: Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
Study NCT06544642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT05281952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ligation
Description: the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
Study NCT05281952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-selective embolization
Description: occlusion of the terminal branches of the nasal external carotid artery.
Study NCT05573828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG angiography to show vascular map of parathyroid glands
Description: Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
Study NCT05617443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stackable guide
Description: different types of stackable guide
Study NCT05617443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stackable guide
Description: different types of stackable guide
Study NCT06119191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses (comfilcon A with current process)
Description: Daily wear lenses for 4 weeks
Study NCT06119191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses (comfilcon A with novel process)
Description: Daily wear lenses for 4 weeks
Study NCT05904106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax plus Azacitidine
Description: Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7
Study NCT05904106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care chemotherapy plus gemtuzumab ozogamicin
Description: Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3
Study NCT06360601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Injection
Description: Labetalol intravenous infusion 20ml/hr
Study NCT06360601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HydrALAZINE Injection
Description: Hydralazine intravenous infusion 5mg/hr
Study NCT06224426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric high-concentration oxygen
Description: During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
Study NCT06224426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric low-concentration oxygen
Description: During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
Study NCT06523283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Landscape Pictures Accompanied by Music
Description: after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
Study NCT06306053 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: tDCS+EuleriaLab
Description: Home based: Non invasive Neuromodulation treatment + Motor Training
Study NCT06306053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Non invasive brain stimulation
Study NCT06306053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EuleriaLab
Description: Home Motor Training
Study NCT05089162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
Study NCT05089162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds
Description: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
Study NCT05089162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
Study NCT05089162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
Study NCT05089162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study NCT06310200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical 4% Topical Solution
Description: Intranasal administration
Study NCT06310200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bitrex
Description: Bittering agent
Study NCT06310200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo